Description
Lipvas (Atorvastatin) 40 mg
Lipvas 40 mg is a branded presentation of atorvastatin, a statin medicine used to help lower blood lipids and reduce cardiovascular risk in appropriate patients. The verified active ingredient is atorvastatin, and the 40 mg strength is one of the established tablet strengths for this medicine.
Active Ingredient and Medicine Class
Atorvastatin belongs to the HMG-CoA reductase inhibitor class, commonly known as statins. These medicines are designed to lower low-density lipoprotein cholesterol (LDL-C) and improve overall lipid profiles. Atorvastatin is an oral film-coated tablet formulation.
Established Medical Uses
Atorvastatin is used as an adjunct to diet and other lipid-lowering measures for several established lipid disorders, including primary hypercholesterolemia, mixed dyslipidemia, hypertriglyceridemia, and certain hereditary cholesterol disorders. It is also used to reduce cardiovascular risk in selected adults, including those with multiple coronary heart disease risk factors, type 2 diabetes with additional risk factors, or established atherosclerotic disease.
In some settings, atorvastatin is used in children and adolescents with heterozygous familial hypercholesterolemia or homozygous familial hypercholesterolemia under appropriate medical supervision.
How It Works
Atorvastatin works by inhibiting HMG-CoA reductase, a key liver enzyme involved in cholesterol production. This decreases the liver’s cholesterol synthesis and increases the number of LDL receptors on liver cells, which helps remove LDL cholesterol from the bloodstream. The result is a dose-related reduction in LDL-C, with additional effects on total cholesterol, triglycerides, and, in some patients, HDL-C.
Important Safety Information
Atorvastatin should not be used in people with acute liver failure or decompensated cirrhosis, or in those with hypersensitivity to atorvastatin or any excipient. Important precautions include the risk of muscle toxicity, including myopathy and rhabdomyolysis, and the possibility of liver enzyme elevations or other hepatic injury. Risk of muscle-related adverse effects is higher in some patients, including older adults, those with uncontrolled hypothyroidism, renal impairment, or certain interacting medicines.
Clinically significant interactions are well recognised. Some drugs and grapefruit juice can increase atorvastatin exposure and raise the risk of muscle toxicity. Rifampin can reduce atorvastatin concentrations. Atorvastatin may also increase levels of some co-administered medicines, including certain oral contraceptives and digoxin.
Atorvastatin may cause fetal harm, and breastfeeding is not recommended during treatment.
Possible Side Effects
Commonly reported adverse effects include muscle symptoms, diarrhea, nausea, abdominal discomfort, and increases in liver enzymes. Other reported effects can include headache and joint or limb pain. More serious but less common reactions include myopathy, rhabdomyolysis, immune-mediated necrotizing myopathy, severe hypersensitivity reactions, and clinically important liver injury.
Scientific Evidence
Human clinical studies have consistently shown that atorvastatin lowers LDL cholesterol in a dose-related manner, with higher doses producing larger lipid reductions. Systematic review evidence also supports meaningful reductions in LDL-C across the usual dose range, and statin-based LDL lowering has been associated with fewer ischemic cardiovascular events and stroke in broader statin meta-analyses. These findings support atorvastatin’s established role in lipid management, although individual clinical benefit depends on the patient’s overall cardiovascular risk profile.
Medical Information Notice
This page is an educational summary based on sources available at the time of review. It does not replace the official patient leaflet, product-specific prescribing information, or assessment by a qualified healthcare professional.
Medical Sources
- U.S. National Library of Medicine, DailyMed Atorvastatin calcium tablet, film coated. View official prescribing information
- J W Nawrocki et al. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arteriosclerosis, Thrombosis, and Vascular Biology, 1995. View scientific article
- Stephen P Adams et al. Lipid-lowering efficacy of atorvastatin. Cochrane Database of Systematic Reviews, 2015. View scientific article
